Abstract:  The double mutation of epithelial growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) is a rare molecular event, with an incidence of 1.3%-1.6%. Its clinicopathological features are still unclear, and no final conclusion has yet been reached on its therapeutic strategies, especially on the selection of its targeted drugs. This paper reports the clinical data of one female lung adenocarcinoma patient with the coexistence of double mutations of EGFR and ALK admitted to Weihai Central Hospital in November 2021, and reviews the pertinent literatures, hoping to provide clinical references for the treatment of this kind of disease. Moreover, follow-up observation is performed for her treatment processes and adverse reactions during the treatment, and now it is reported as follows.

Key words: Lung malignant tumors, Gene mutation, Targeted drugs

摘要： 表皮生长因子受体（epithelial growth factor receptor，EGFR）和间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）双突变作为罕见分子事件，发生率为1.3%～1.6%，其临床病理特点还不是很清楚，治疗策略尚无定论，尤其是靶向药物的选择。本文报道威海市中心医院2021年11月收治的1例EGFR和ALK基因双突变共存女性肺腺癌患者临床资料，并复习相关文献，以期为该类患者的治疗提供临床借鉴，对于其治疗经过及治疗过程中出现的不良反应进行了随访观察，现报道如下。

关键词: 肺恶性肿瘤, 基因突变, 靶向药物